Inventor · disambiguated record
Saar Gill
Also filed as: GILL SAAR
31 granted patents·30 pending applications·303 citations·filing 2014–2024
96Inventor score
Top patents by PatentIndex Score
61 records- 0197US11191784B2Methods and composition for gene delivery using an engineered viral particleUNIV PENNSYLVANIA·Filed 2021·Granted Dec 7, 2021·4 cites·23 claims
- 0297US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0397US9573988B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsBROGDON JENNIFER·Filed 2014·Granted Feb 21, 2017·87 cites·94 claims
- 0496US11034749B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2016·Granted Jun 15, 2021·10 cites·28 claims
- 0596US10253086B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2016·Granted Apr 9, 2019·37 cites·35 claims
- 0695US12163119B2Methods and composition for gene delivery using an engineered viral particleUNIV PENNSYLVANIA·Filed 2023·Granted Dec 10, 2024·1 cites·19 claims
- 0795US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0894US11149076B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2019·Granted Oct 19, 2021·9 cites·32 claims
- 0994US11026976B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2019·Granted Jun 8, 2021·6 cites·23 claims
- 1093US11872249B2Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domainNOVARTIS AG·Filed 2021·Granted Jan 16, 2024·2 cites·38 claims
- 1192US10548922B2Methods and compositions for gene editing in hematopoietic stem cellsUNIV PENNSYLVANIA·Filed 2018·Granted Feb 4, 2020·17 cites·20 claims
- 1291US11028177B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsNOVARTIS AG·Filed 2017·Granted Jun 8, 2021·4 cites·47 claims
- 1389US12344657B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2021·Granted Jul 1, 2025·1 cites·27 claims
- 1487US11673964B2Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemiasUNIV PENNSYLVANIA·Filed 2019·Granted Jun 13, 2023·2 cites·20 claims
- 1586US12227588B2Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemiasUNIV PENNSYLVANIA·Filed 2024·Granted Feb 18, 2025·0 cites·22 claims
- 1686US11306133B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2020·Granted Apr 19, 2022·1 cites·13 claims
- 1785US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 1885US2023279074A1Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses ThereofUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 1983US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 2082US11498954B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2022·Granted Nov 15, 2022·0 cites·24 claims
- 2181US11747346B2Biomarkers predictive of cytokine release syndromeUNIV PENNSYLVANIA·Filed 2016·Granted Sep 5, 2023·3 cites·25 claims
- 2281US11407805B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2021·Granted Aug 9, 2022·0 cites·30 claims
- 2381US11359002B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2021·Granted Jun 14, 2022·0 cites·17 claims
- 2481US11332511B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2021·Granted May 17, 2022·0 cites·30 claims
- 2581US11325963B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2021·Granted May 10, 2022·0 cites·27 claims
- 2681US11319358B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2021·Granted May 3, 2022·0 cites·24 claims
- 2781US11306134B2Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereofUNIV PENNSYLVANIA·Filed 2021·Granted Apr 19, 2022·0 cites·27 claims
- 2880US2023374105A1Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cellNOVARTIS AG·Filed 2023·Application pending·0 cites
- 2979USRE49847ENucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2022·Granted Feb 27, 2024·0 cites·35 claims
- 3079US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3178US11723927B2Methods and composition for gene delivery using an engineered viral particleUNIV PENNSYLVANIA·Filed 2021·Granted Aug 15, 2023·0 cites·20 claims
- 3277US2023331864A1Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and LeukemiasUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 3376US2025163148A1Anti-car compositions and methodsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 3476US2025154530A1Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregatesUNIV PENNSYLVANIA·Filed 2024·Application pending·0 cites
- 3574US2023034117A1Compositions and methods for regulating car t cellsUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 3674US2024066064A1Methods and compositions for gene editing in hematopoietic stem cellsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 3771US11771719B2Methods and compositions for gene editing in hematopoietic stem cellsUNIV PENNSYLVANIA·Filed 2019·Granted Oct 3, 2023·0 cites·9 claims
- 3871US2024383965A1Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cellsUNIV PENNSYLVANIA·Filed 2024·Application pending·0 cites
- 3970US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 4068US11884716B2Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cellsUNIV PENNSYLVANIA·Filed 2021·Granted Jan 30, 2024·0 cites·18 claims
- 4167US2025057883A1Controllable stimulation of genetically engineered lymphocytes for the treatment of cancerUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 4267US2025041339A1Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell TherapyUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 4366US2025367288A1Delivery of multi-cytokine signals by overexpression of wild-type or mutant signal transduction moleculesUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 4466US2024288444A1Biomarkers predictive of cytokine release syndromeNOVARTIS AG·Filed 2023·Application pending·0 cites
- 4565US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4663US2025025558A1Engineered Chimeric Antigen Receptor (CAR) Microglia-Like Cells for the Treatment of Neurodegenerative DisordersUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 4762US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4861US2021046110A1Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregatesUNIV PENNSYLVANIA·Filed 2019·Application pending·0 cites
- 4961US2021179709A1Anti-car compositions and methodsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 5059US2021095001A1Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cellsUNIV PENNSYLVANIA·Filed 2019·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Saar Gill files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →